Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury

Kidney International

Volumn 82, Issue 11, 2012, Pages 1195-1207

  Chen, Jianlin ^a   Matzuk, Martin M ^b   Zhou, Xin J ^c   Lu, Christopher Y ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Renal Path Diagnostics Pathologists BioMedical Laboratories   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

acute kidney injury; acute renal failure; endothelial cells; renal ischemia reperfusion injury

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH MOBILITY GROUP B1 PROTEIN; HYDROGEN PEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PENTRAXIN 3; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENDOTHELIUM CELL; INTRACELLULAR SIGNALING; KIDNEY ISCHEMIA; LEUKOCYTE MIGRATION; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

EID: 84869237641     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.268     Document Type: Article

References (91)

1. Hsu CY, McCulloch CE, Fan D et al. Community-based incidence of acute renal failure. Kidney Int 2007; 72: 208-212. (Pubitemid 47067390)
2. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81: 442-448.
3. Venkatachalam MA, Griffin KA, Lan R et al. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1078.
4. Rosin DL, Okusa MD. Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol 2011; 22: 416-425.
5. Chen J, John R, Richardson JA et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int 2011; 79: 288-299.
6. Inforzato A, Jaillon S, Moalli F et al. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens 2011; 77: 271-282.
7. Kume N, Mitsuoka H, Hayashida K et al. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol 2011; 58: 38-45.
8. Ryu WS, Kim CK, Kim BJ et al. Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 2012; 220: 581-586.
9. Zinellu A, Caria MA, Tavera C et al. Plasma creatinine and creatine quantification by capillary electrophoresis diode array detector. Anal Biochem 2005; 342: 186-193. (Pubitemid 40884565)
10. Yuen PS, Dunn SR, Miyaji T et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004; 286: F1116-F11F9.
11. Dunn SR, Qi Z, Bottinger EP et al. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004; 65: 1959-1967. (Pubitemid 38591050)
12. Waikar SS, Betensky RA, Emerson SC et al. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 2012; 23: 13-21.
13. Horbelt M, Lee SY, Mang HE et al. Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 2007; 293: F688-F695. (Pubitemid 47403338)
14. Sutton TA, Mang HE, Campos SB et al. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 2003; 285: F191-F198. (Pubitemid 36871191)
15. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
16. Szeto HH, Liu S, Soong Y et al. Mitochodria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol 2011; 22: 1041-1052.
17. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn-Schmiedebergs Arch Pharmacol [Review] 2007; 376: 1-43. (Pubitemid 350161567)
18. Hall AM. Pores for thought: new strategies to re-energize stressed mitochondria in acute kidney injury. J Am Soc Nephrol 2011; 22: 986-989.
19. Arbiser JL, Moses MA, Fernandez CA et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94: 861-866. (Pubitemid 27074412)
20. Arbiser JL, Larsson H, Claesson-Welsh L et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol 2000; 156: 1469-1476. (Pubitemid 30660021)
21. Wu H, Chen G, Wyburn KR et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847-2859. (Pubitemid 47529615)
22. Shigeoka AA, Holscher TD, King AJ et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J Immunol 2007; 178: 6252-6258. (Pubitemid 46717408)
23. Pulskens WP, Teske GJ, Butter LM et al. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS ONE 2008; 3: e3596.
24. Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and-extrinsic mechanisms. Immunity 2008; 29: 272-282.
25. Schlaeger TM, Bartunkova S, Lawitts JA et al. Uniform vascularendothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997; 94: 3058-3063. (Pubitemid 27157263)
26. Kisanuki YY, Hammer RE, Miyazaki J et al. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 2001; 230: 230-242. (Pubitemid 32171420)
27. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-18.
28. Hauser P, Kainz A, Perco P et al. Transcriptional response in the unaffected kidney after contralateral hydronephrosis or nephrectomy. Kidney Int 2005; 68: 2497-2507. (Pubitemid 43250996)
29. Sarrazin S, Adam E, Lyon M et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37. (Pubitemid 41752939)
30. Villanueva S, Cespedes C, Gonzalez A et al. bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1677-R1687. (Pubitemid 44904135)
31. Villanueva S, Cespedes C, Gonzalez AA et al. Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2008; 294: R819-R828. (Pubitemid 351346958)
32. Goligorsky MS, Brodsky SV, Noiri E. Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int 2002; 61: 855-861. (Pubitemid 34175452)
33. Legrand M, Mik EG, Johannes T et al. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med 2008; 14: 502-516.
34. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66: 480-485. (Pubitemid 38981982)
35. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130: 41-50.
36. Lin SL, Li B, Rao S et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci USA 2010; 107: 4194-4199.
37. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
38. Gandolfo MT, Jang HR, Bagnasco SM et al. Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion. Transpl Immunol 2010; 23: 45-52.
39. Kinsey GR, Huang L, Vergis AL et al. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 2010; 77: 771-780.
40. Lai LW, Yong KC, Lien YH. Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury. Kidney Int 2012; 81: 983-992.
41. Kielar ML, John R, Bennett M et al. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol 2005; 16: 3315-3325. (Pubitemid 46179335)
42. Souza DG, Soares AC, Pinho V et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002; 160(bett5): 1755-1765. (Pubitemid 34525655)
43. Souza DG, Amaral FA, Fagundes CT et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol 2009; 174: 1309-1318.
44. Haas MS, Alicot EM, Schuerpf F et al. Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res 2010; 87: 618-627.
45. Salio M, Chimenti S, De Angelis N et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117: 1055-1064.
46. Renner B, Strassheim D, Amura CR et al. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 2010; 185: 4393-4400.
47. Zhou W, Farrar CA, Abe K et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363-1371. (Pubitemid 30322402)
48. Ricklin D, Hajishengallis G, Yang K et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
49. Thurman JM, Renner B. Dynamic control of the complement system by modulated expression of regulatory proteins. Lab Invest 2011; 91: 4-11.
50. Bao L, Wang Y, Chang A et al. Unrestricted C3 activation occurs in Crrydeficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007; 18: 811-822. (Pubitemid 46434498)
51. Deban L, Jarva H, Lehtinen MJ et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and Function in the regulation of complement activation. J Immunol 2008; 181: 8433-8440.
52. Jaillon S, Peri G, Delneste Y et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204: 793-804. (Pubitemid 46631609)
53. Salustri A, Garlanda C, Hirsch E et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004; 131: 1577-1586. (Pubitemid 38559284)
54. Scarchilli L, Camaioni A, Bottazzi B et al. PTX3 interacts with inter-alphatrypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J Biol Chem 2007; 282: 30161-30170. (Pubitemid 350035268)
55. Janssen U, Thomas G, Glant T et al. Expression of inter-alpha-trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells. Kidney Int 2001; 60: 126-136. (Pubitemid 32587547)
56. Bommaya G, Meran S, Krupa A et al. Tumour necrosis factor-stimulated gene (TSG)-6 controls epithelial-mesenchymal transition of proximal tubular epithelial cells. Int J Biochem Cell Biol 2011; 43: 1739-1746.
57. Bottazzi B, Garlanda C, Cotena A et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009; 227: 9-18.
58. Wu H, Ma J, Wang P et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010; 21: 1878-1890.
59. Li J, Gong Q, Zhong S et al. Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2010; 26: 469-478.
60. Yang H, Hreggvidsdottir HS, Palmblad K et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-11947.
61. Dessing MC, Pulskens WP, Teske GJ et al. RAGE does not contribute to renal injury and damage upon ischemia/reperfusion-induced injury. J Innate Immun 2012; 4: 80-85.
62. Rusai K, Sollinger D, Baumann M et al. Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr Nephrol 2010; 25: 853-860.
63. Chen J, Hartono J, John R et al. Interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int 2011; 80: 504-515.
64. Kruger B, Krick S, Dhillon N et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009; 106: 3390-3395.
65. Kelly KJ, Williams Jr WW, Colvin RB et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056-1063. (Pubitemid 26070586)
66. Kelly KJ, Williams Jr WW, Colvin RB et al. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1995; 91: 812-816. (Pubitemid 24041492)
67. Rabb H, Mendiola CC, Dietz J et al. Role of CD11a and CD11b in ischemic acute renal failure in rats. Am J Physiol 1994; 267: F1052-F1058. (Pubitemid 124005387)
68. Kiew LV, Munavvar AS, Law CH et al. Effect of antisense oligodeoxynucleotides for ICAM-1 on renal ischaemia-reperfusion injury in the anaesthetised rat. J Physiol 2004; 557(Part 3): 981-989. (Pubitemid 38961630)
69. Haller H, Dragun D, Miethke A et al. Antisense oligonucleotides for ICAM 1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996; 50: 473-480. (Pubitemid 26274374)
70. O'Neill LA. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 2008; 29: 12-20. (Pubitemid 351952460)
71. Bezbradica JS, Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol 2009; 10: 333-339.
72. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 2010; 67: 4109-4134.
73. You R, Zheng M, McKeown-Longo PJ. The first type III repeat in fibronectin activates an inflammatory pathway in dermal fibroblasts. J Biol Chem 2010; 285: 36255-36259.
74. Mittal D, Saccheri F, Venereau E et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010; 29: 2242-2252.
75. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; 2010: 1-21.
76. Leali D, Alessi P, Coltrini D et al. Long pentraxin-3 inhibits FGF8bdependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther 2011; 10: 1600-1610.
77. Leali D, Bianchi R, Bugatti A et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med 2010; 14: 2109-2121.
78. Rusnati M, Camozzi M, Moroni E et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-99. (Pubitemid 38879843)
79. Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int 2011; 80: 29-40.
80. Rovere P, Peri G, Fazzini F et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000; 96: 4300-4306.
81. Baruah P, Dumitriu IE, Peri G et al. The tissue pentraxin PTX3 limits C1qmediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 2006; 80: 87-95. (Pubitemid 44835529)
82. van Rossum AP, Fazzini F, Limburg PC et al. The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 2004; 50: 2667-2674. (Pubitemid 39062730)
83. van Rossum AP, Pas HH, Fazzini F et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006; 54: 986-991.
84. Poon IK, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ 2010; 17: 381-397.
85. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010; 10: 36-46.
86. Peter C, Wesselborg S, Herrmann M et al. Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis 2010; 15: 1007-1028.
87. Matsuda A, Wu R, Jacob A et al. Protective effect of milk fat globuleepidermal growth factor-factor VIII after renal ischemia-reperfusion injury in mice. Crit Care Med 2011; 39: 2039-2047.
88. Harrois A, Duranteau J. Acute kidney injury: clear the kidney of apoptotic debris!. Crit Care Med 2011; 39: 2180-2181.
89. Matsuda A, Jacob A, Wu R et al. Milk fat globule-EGF factor VIII in sepsis and ischemia-reperfusion injury. Mol Med 2011; 17: 126-133.
90. de Lange WJ, Halabi CM, Beyer AM et al. Germ line activation of the Tie2 and SMMHC promoters causes noncell-specific deletion of floxed alleles. Physiol Genomics 2008; 35: 1-4.
91. Varani S, Elvin JA, Yan C et al. Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. Mol Endocrinol 2002; 16: 1154-1167. (Pubitemid 34621066)